Mells, George F.

Genome-wide association study identifies 12 new susceptibility loci for primary biliary cirrhosis

The UK PBC Consortium, Mells, G. F., The Wellcome Trust Case Control Consortium 3, Floyd, J. A. B., Morley, K. I., Cordell, H. J., Franklin, C. S., Shin, S.-Y., Heneghan, M. A., Neuberger, J. M., et al. (2011) · Nature Genetics

Liver Diseases and ImmunityGenetic Associations and Epidemiology

Cited by 464

Cholangiocyte organoids can repair bile ducts after transplantation in the human liver

Sampaziotis, F., Muraro, D., Tysoe, O. C., Sawiak, S., Beach, T. E., Godfrey, E. M., Upponi, S. S., Brevini, T., Wesley, B. T., Garcia-Bernardo, J., et al. (2021) · Science

Liver physiology and pathologyOrgan Transplantation Techniques and Outcomes

Cited by 394

Sex and age are determinants of the clinical phenotype of primary biliary cirrhosis and response to ursodeoxycholic Acid

Carbone, M., Mells, G. F., Pells, G., Dawwas, M. F., Newton, J. L., Heneghan, M. A., Neuberger, J. M., Day, D. B., Ducker, S. J., Sandford, R. N., et al. (2013) · Gastroenterology

Liver Diseases and ImmunityPediatric Hepatobiliary Diseases and Treatments

Cited by 386

Genome-wide association study of primary sclerosing cholangitis identifies new risk loci and quantifies the genetic relationship with inflammatory bowel disease

The UK-PSC Consortium, Ji, S.-G., The International IBD Genetics Consortium, The International PSC Study Group, Juran, B. D., Mucha, S., Folseraas, T., Jostins, L., Melum, E., Kumasaka, N., et al. (2017) · Nature Genetics

Liver Diseases and ImmunityGenetic Associations and Epidemiology

Cited by 357

The UK‐PBC risk scores: Derivation and validation of a scoring system for long‐term prediction of end‐stage liver disease in primary biliary cholangitis

Carbone, M., Sharp, S. J., Flack, S., Paximadas, D., Spiess, K., Adgey, C., Griffiths, L., Lim, R., Trembling, P., Williamson, K., et al. (2016) · Hepatology

Liver Diseases and ImmunityPediatric Hepatobiliary Diseases and Treatments

Cited by 354

International genome-wide meta-analysis identifies new primary biliary cirrhosis risk loci and targetable pathogenic pathways

Cordell, H. J., Han, Y., Mells, G. F., Li, Y., Hirschfield, G. M., Greene, C. S., Xie, G., Juran, B. D., Zhu, D., Qian, D. C., et al. (2015) · Nature Communications

Liver Diseases and ImmunityGenetic Associations and Epidemiology

Cited by 287

Dense fine-mapping study identifies new susceptibility loci for primary biliary cirrhosis

The UK Primary Biliary Cirrhosis (PBC) Consortium, Liu, J. Z., The Wellcome Trust Case Control Consortium 3, Almarri, M. A., Gaffney, D. J., Mells, G. F., Jostins, L., Cordell, H. J., Ducker, S. J., Day, D. B., et al. (2012) · Nature Genetics

Liver Diseases and ImmunityGenetic Associations and Epidemiology

Cited by 274

Impact of primary biliary cirrhosis on perceived quality of life: The UK-PBC national study

Mells, G. F., Pells, G., Newton, J. L., Bathgate, A. J., Burroughs, A. K., Heneghan, M. A., Neuberger, J. M., Day, D. B., Ducker, S. J., Sandford, R. N., et al. (2013) · Hepatology

Liver Diseases and ImmunityPediatric Hepatobiliary Diseases and Treatments

Cited by 227

Seladelpar (MBX-8025), a selective PPAR-δ agonist, in patients with primary biliary cholangitis with an inadequate response to ursodeoxycholic acid: a double-blind, randomised, placebo-controlled, phase 2, proof-of-concept study

Jones, D., Boudes, P. F., Swain, M. G., Bowlus, C. L., Galambos, M. R., Bacon, B. R., Doerffel, Y., Gitlin, N., Gordon, S. C., Odin, J. A., et al. (2017) · The Lancet Gastroenterology & Hepatology

Liver Diseases and ImmunityPeroxisome Proliferator-Activated Receptors

Cited by 191

The inter-relationship of symptom severity and quality of life in 2055 patients with primary biliary cholangitis

Dyson, J. K., Wilkinson, N., Jopson, L., Mells, G., Bathgate, A., Heneghan, M. A., Neuberger, J., Hirschfield, G. M., Ducker, S. J., The UK‐PBC Consortium, et al. (2016) · Alimentary Pharmacology & Therapeutics

Liver Diseases and ImmunityPediatric Hepatobiliary Diseases and Treatments

Cited by 78

X Chromosome Contribution to the Genetic Architecture of Primary Biliary Cholangitis

Asselta, R., Paraboschi, E. M., Gerussi, A., Cordell, H. J., Mells, G. F., Sandford, R. N., Jones, D. E., Nakamura, M., Ueno, K., Hitomi, Y., et al. (2021) · Gastroenterology

Liver Diseases and ImmunityGenetic Associations and Epidemiology

Cited by 55

The Serum Proteome and Ursodeoxycholic Acid Response in Primary Biliary Cholangitis

Barron‐Millar, B., Ogle, L., Mells, G., Flack, S., Badrock, J., Sandford, R., Kirby, J., Palmer, J., Jopson, L., Brain, J., et al. (2021) · Hepatology

Liver Diseases and ImmunityDrug Transport and Resistance Mechanisms

Cited by 45

Primary biliary cholangitis drug evaluation and regulatory approval: Where do we go from here?

Jones, D. E. J., Beuers, U., Bonder, A., Carbone, M., Culver, E., Dyson, J., Gish, R. G., Hansen, B. E., Hirschfield, G., Jones, R., et al. (2024) · Hepatology

Liver Diseases and ImmunityPediatric Hepatobiliary Diseases and Treatments

Cited by 38

Effects of Primary Biliary Cholangitis on Quality of Life and Health Care Costs in the United Kingdom

Rice, S., Albani, V., Minos, D., Fattakhova, G., Mells, G. F., Carbone, M., Flack, S., Varvaropoulou, N., Badrock, J., Spicer, A., et al. (2021) · Clinical Gastroenterology and Hepatology

Liver Diseases and ImmunityHealth Systems, Economic Evaluations, Quality of Life

Cited by 32

Bacterial and metabolic phenotypes associated with inadequate response to ursodeoxycholic acid treatment in primary biliary cholangitis

Martinez-Gili, L., Pechlivanis, A., McDonald, J. A. K., Begum, S., Badrock, J., Dyson, J. K., Jones, R., Hirschfield, G., Ryder, S. D., Sandford, R., et al. (2023) · Gut Microbes

Liver Diseases and ImmunityGut microbiota and health

Cited by 32

Critical shortfalls in the management of PBC: Results of a UK-wide, population-based evaluation of care delivery

Abbas, N., Smith, R., Flack, S., Bains, V., Aspinall, R. J., Jones, R. L., Burke, L., Thorburn, D., Heneghan, M., Yeoman, A., et al. (2024) · JHEP Reports

Liver Diseases and ImmunityPediatric Hepatobiliary Diseases and Treatments

Cited by 31

Quality of life in patients with primary biliary cholangitis: A cross-geographical comparison

Montali, L., Gragnano, A., Miglioretti, M., Frigerio, A., Vecchio, L., Gerussi, A., Cristoferi, L., Ronca, V., D’Amato, D., O’Donnell, S. E., et al. (2021) · Journal of Translational Autoimmunity

Liver Diseases and ImmunityPediatric Hepatobiliary Diseases and Treatments

Cited by 26

The relationship between disease activity and UDCA response criteria in primary biliary cholangitis: A cohort study

Jones, D. E. J., Wetten, A., Barron-Millar, B., Ogle, L., Mells, G., Flack, S., Sandford, R., Kirby, J., Palmer, J., Brotherston, S., et al. (2022) · eBioMedicine

Liver Diseases and ImmunityPediatric Hepatobiliary Diseases and Treatments

Cited by 22

Anti-Cholestatic Therapy with Obeticholic Acid Improves Short-Term Memory in Bile Duct-Ligated Mice

Gee, L. M. V., Barron-Millar, B., Leslie, J., Richardson, C., Zaki, M. Y. W., Luli, S., Burgoyne, R. A., Cameron, R. I. T., Smith, G. R., Brain, J. G., et al. (2023) · The American Journal of Pathology

Liver Diseases and ImmunityDrug Transport and Resistance Mechanisms

Cited by 18

P1198 : Histological stage is relevant for risk-stratification in primary biliary cirrhosis

Carbone, M., Sharp, S. J., Heneghan, M. A., Neuberger, J. M., Hirschfield, G. M., Burroughs, A. K., Thorburn, D., Bathgate, A., Aldersley, M., Adgey, C., et al. (2015) · Journal of Hepatology

Liver Diseases and ImmunityPediatric Hepatobiliary Diseases and Treatments

Cited by 15

P1152: a comparative study of pruritus in PBC cohorts from UK, USA and Italy

Hegade, V. S., Mells, G. F., Lammert, C., Juran, B., Lleo, A., Carbone, M., Lazaridis, K., Invernizzi, P., Kendrick, S., Sandford, R., et al. (2015) · Journal of Hepatology

Liver Diseases and ImmunityDermatology and Skin Diseases

Cited by 15

Making the most of new genetic risk factors – genetic and epigenetic fine mapping of causal autoimmune disease variants

Mells, G. F., & Hirschfield, G. M. (2015) · Clinics and Research in Hepatology and Gastroenterology

Genetic Associations and EpidemiologyBioinformatics and Genomic Networks

Cited by 8

Optimising Primary thErapy in pRimAry biliary cholangitis (OPERA): protocol for a randomised, double-blind, placebo-controlled trial of enhanced primary therapy with obeticholic acid

Dunn, S., Evans, L., Kennedy, C., Wafer, R., Moody, S., Wolstenhulme, F., Burton, E., Konkoth, A. B., Fisher, H., Chadwick, T., et al. (2026) · BMJ Open

Liver Diseases and ImmunityDrug Transport and Resistance Mechanisms

Cited by 0